Ensysce Biosciences (ENSC) Stock: Buy, Sell, or Hold?
ENSC - Ensysce Biosciences, Inc. Common Stock
$0.52
0.02 (4.29%)
â˛
5d:
-7.31%
30d:
+21.21%
90d:
+90.76%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When ENSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENSC is currently trading at $0.52, which is considered slightly high relative to its 30-day fair value range of $0.41 to $0.52.
Technical Outlook: Technically, ENSC is in a strong uptrend. Immediate support is located at $0.40, while resistance sits at $0.62. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: ENSC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+1486.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENSC is in a strong uptrend. Immediate support is located at $0.40, while resistance sits at $0.62. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: ENSC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+1486.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.41 -
$0.52
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 1486.5% below Wall St target ($8.25)
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.41 -
$0.52
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$0.62
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.40
Wall Street Target
$8.25
(+1486.5%)
Revenue Growth (YoY)
-15.1%
Profit Margin
-280.5%
Share & Embed Analysis
Last updated: October 22, 2026 7:44 AM ET
Data refreshes hourly during market hours. Next update: 8:44 AM
Data refreshes hourly during market hours. Next update: 8:44 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
20 analysts |
$650 | 50 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 63 BUY |
